Minerva Neurosciences (NERV) risk factors
Item 1A of every Minerva Neurosciences, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors94 risks5 new6 dropped11 reworded
Minerva Neurosciences added specific risks regarding Series A preferred stock dilution, EU pharmaceutical regulatory overhauls, and trade compliance. Federal net operating loss carryforwards grew from $156.8 million to $188.2 million.
Filed Mar 11, 2026 - FY2024 10-K risk factors95 risks
Minerva Neurosciences faces ongoing operational losses and needs additional capital to advance its clinical pipeline. The company is heavily dependent on regulatory approval and successful commercialization of roluperidone and MIN-301. Intensive competition and pricing pressures in the central nervous system therapeutics market threaten future profitability.
Filed Feb 25, 2025